This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

Several DPP-4 inhibitors are in clinical development; these are orally active and increase levels of active GLP-1, which in turn increases insulin secretion and reduces glucagon secretion and ...

Other oral drugs like DPP-4 inhibitors work by telling your pancreas to release more insulin at mealtimes and reduce the release of glucose from your liver. GLP-1 receptor agonists, a class of ...

dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide 1 (GLP-1) agonists. Among these medications, sulfonylureas are the oldest and most widely used; however, both DPP-4 inhibitors ...

Use of SGLT2 inhibitors was associated with a lower risk for rhabdomyolysis than DPP-4 inhibitors among statin users. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with a ...

In the present study, the researchers compared the impact of two antiglycemic drugs, SGLT-2 inhibitors and DPP-4 inhibitors, ...